A novel frameshift mutation of Chediak-Higashi syndrome and treatment in the accelerated phase

10Citations
Citations of this article
26Readers
Mendeley users who have this article in their library.

Abstract

Chediak-Higashi syndrome (CHS) is a rare autosomal recessive immunodeficiency disease characterized by frequent infections, hypopigmentation, progressive neurologic deterioration and hemophagocytic lymphohistiocytosis (HLH), known as the accelerated phase. There is little experience in the accelerated phase of CHS treatment worldwide. Here, we present a case of a 9-month-old boy with continuous high fever, hypopigmentation of the skin, enlarged lymph nodes, hepatosplenomegaly and lung infection. He was diagnosed with CHS by gene sequencing, and had entered the accelerated phase. After 8 weeks of therapy, the boy had remission and was prepared for allogenic stem cell transplantation.

Cite

CITATION STYLE

APA

Wu, X. L., Zhao, X. Q., Zhang, B. X., Xuan, F., Guo, H. M., & Ma, F. T. (2017). A novel frameshift mutation of Chediak-Higashi syndrome and treatment in the accelerated phase. Brazilian Journal of Medical and Biological Research, 50(4). https://doi.org/10.1590/1414-431X20165727

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free